Noul, a South Korean company specializing in AI-powered diagnostics, unveiled its cervical cancer screening solution miLab CER at CES 2026 in Las Vegas. The device automates the diagnostic process and delivers results in under 20 minutes.
Cervical cancer remains one of the leading causes of cancer-related deaths among women globally, with approximately 660,000 new cases and 350,000 deaths reported each year. The World Health Organization has set a target to increase global cervical cancer screening coverage to 70% by 2030.
The miLab CER device automates cervical cell slide staining, digital imaging, AI-based analysis, and report generation within a single compact unit. According to the company, the system replaces approximately 25 manual staining and preparation steps, reducing diagnostic workflows by 80%.
In performance evaluations, miLab CER demonstrated 93.9% sensitivity and 97.8% specificity using ASCUS+ criteria, which the company says is comparable to conventional expert-led pathology assessments.
“miLab CER was developed to address disparities in women’s health caused by uneven healthcare access,” said David Lim, CEO of Noul. “By enabling consistent cervical cancer diagnostics anywhere in the world, we aim to advance global health equity while leading a shift toward more consumer-centric diagnostic models.”
The device uses what Noul describes as NGSI (Next Generation Staining and Immunostaining) solid-staining technology, which eliminates the use of methanol, minimizes reagent consumption, and generates minimal wastewater.
In 2024, Unitaid recommended miLab CER for use alongside solutions from Roche and Hologic. Noul plans to extend its automated AI diagnostic technologies to additional disease areas beyond cervical cancer.
